IL17C

Across TCGA pan-cancer cohorts, IL17C Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IL17C data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher IL17C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL17C expression acts as an unfavorable survival marker.

CESC, SKCM, and SARC are the cancer types where IL17C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.163	0.835	<.001	28	view →
SKCM	DFS	Median	All	0.267	0.742	<.001	18	view →
SARC	OS	Median	All	0.016	0.861	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IL17C–CESC (OS)

Open the CESC breakdown →